This article is based on a poster originally authored by Daniel Weekes, Blaise Louis, Sunil Modi, Erica Bello, Serena Belluschi, Tom Mitchell, Holly Herbert, Tarun Vemulkar, and Jeroen Verheyen, which ...
This article is based on a poster originally authored by Blaise Louis, Serena Belluschi, Daniel Weekes, Tom Mitchell, Holly Herbert, Tarun Vemulkar and Jeroen Verheyen, which was presented at ELRIG ...
CAMBRIDGE, England--(BUSINESS WIRE)--Semarion Ltd, a University of Cambridge spin-out company from the Cavendish Laboratory combining materials engineering and cell biology to tackle unmet drug ...
Drug discovery can be a long and expensive process, spanning up to 10–15 years and costing over $1–2 billion. Addressing bottlenecks at each stage is key to reducing costs and timelines. Molly ...
Funding supports expansion of manufacturing and commercial capacity for SemaCyte microcarrier platform Semarion, a University of Cambridge spin-out company from the Cavendish Laboratory combining ...
Semarion raises £2.14 million GBP (US$2.89 million) seed funding to support the commercial development of Semarion’s SemaCyte cell assaying platform. Semarion Ltd, a University of Cambridge spin-out ...
Expansion to SemaCyte Microcarrier platform enables optical barcoding and pooling of adherent cells to augment drug discovery high-content imaging and other screening processes Access available ...
SPT Labtech, a global leader in innovative laboratory automation, today announced a strategic collaboration with Semarion, a University of Cambridge spin-out company from the Cavendish Laboratory ...
CAMBRIDGE, U.K., March 31, 2026--(BUSINESS WIRE)--Semarion, a University of Cambridge spin-out company from the Cavendish Laboratory combining materials engineering and cell biology to tackle unmet ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results